Business
GEMoaB and Intellia Therapeutics Enter into Research Collaboration and Licensing Agreement on Next-Generation Cellular Immunotherapy Based on Proprietary RevCAR and CRISPR/Cas9 Genome Editing Platforms
GEMoaB and Intellia to Combine Proprietary Technologies and Research and Development Expertise to Create Transformative Allogeneic Cellular Immunotherapies
About this update from Intellia Therapeutics, Inc.
[{"type":"text","content":"GEMoaB and Intellia to Combine Proprietary Technologies and Research and Development Expertise to Create Transformative Allogeneic Cellular Immunotherapies against Promising Targets in Oncology and Inflammatory Diseases\n GEMoaB to Receive Upfront Payments, Regulatory and Commercial Milestone Payments Plus Royalties Based on Net Sales\n\n\n\n DRESDEN, Germany, July 20, 2020 /PRNewswire/ -- GEMoaB, a biopharmaceutical company focused on the development of next-generation immunotherapies for hard-to-treat cancers, announced today that it has entered into a research collaboration and license agreement with Intellia (Nasdaq: NTLA), a global leader in the field of genome editing treatments. \nThe companies will conduct joint research to combine GEMoaB's proprietary RevCAR technology platform with Intellia's proprietary genome editing technologies to discover and develop next-generation allogeneic cellular immunotherapies for hard-to-treat cancers and inflammatory diseases. The companies will focus on immunotherapies directed against a selected number of targets.\nUnder the terms of the agreement, GEMoaB will receive payments for each product based on target reservation and selection, achievement of regulatory, clinical and commercial milestones as well as tiered royalties based on net sales. Intellia will lead the research collaboration, and be responsible for clinical development and commercialization.\n\"We are very pleased to enter into the agreement with Intellia, which is, similarly to GEMoaB, using its cutting-edge technology to develop breakthrough products for patients with a high unmet medical need,\" said Armin Ehninger, Ph.D., Chief Scientific Officer at GEMoaB. \"Not only does the collaboration reflect the unique optionality of GEMoaB's technological platform, but it will also provide rapid clinical proof-of-concept for RevCAR, our second cellular immunotherapy platform.\"\nAndrew Schiermeier, Ph.D., Intellia's Chief Operating Officer, added, \"We are very pleased to work with the talented GEMoaB team, and believe that their RevCAR platform represents a unique and powerful advance in how we think about engineering cell therapies. We are confident that the combined power of GEMoaB's cellular immunotherapy platform and Intellia's numerous and proprietary CRISPR-based approaches to T-cell engineering will accelerate the deve...